Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

EMD SERONO RESEARCH & DEVELOPMENT INSTITUTE, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Cladribine Tablets

First Posted Date: 2019-05-01

Last Posted Date: 2025-04-06

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 291

Registration Number: NCT03933202

Locations: 🇺🇸
North Central Neurology Associates, P.C., Cullman, Alabama, United States
🇺🇸
University of South Alabama, Mobile, Alabama, United States
🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

and more 63 locations

M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Cisplatin
Drug: Docetaxel
Drug: Nab-paclitaxel
Drug: Carboplatin
Drug: Gemcitabine
Drug: Bintrafusp alfa
Drug: Pemetrexed
Drug: M7824
Drug: Paclitaxel

First Posted Date: 2019-02-15

Last Posted Date: 2023-08-21

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 70

Registration Number: NCT03840915

Locations: 🇺🇸
Compassionate Care Research Group Inc - Edinger Medical Group, Inc., Fountain Valley, California, United States
🇺🇸
California Cancer Associates for Research & Excellence, Inc., San Marcos, California, United States
🇺🇸
Hematology - Oncology Associates of Treasure Coast - Hematology-Oncology Associates of Treasure Coast, Port Saint Lucie, Florida, United States

and more 16 locations

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

Phase 2

Terminated

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: M7824
Drug: Placebo
Drug: Durvalumab
Drug: Etoposide
Drug: Pemetrexed
Drug: Carboplatin
Drug: Paclitaxel
Drug: Cisplatin
Radiation: Intensity Modulated Radiation Therapy (IMRT)

First Posted Date: 2019-02-15

Last Posted Date: 2024-01-16

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 153

Registration Number: NCT03840902

Locations: 🇺🇸
University of California Irvine Medical Center, Orange, California, United States
🇺🇸
UCLA Hematology Oncology - Main Site - 2020 Santa Monica, Santa Monica, California, United States
🇺🇸
University of Colorado Health - Memorial Hospital - Memorial Hospital, Colorado Springs, Colorado, United States

and more 101 locations

M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)

Phase 2

Completed

Conditions: Cholangiocarcinoma
Gallbladder Cancer
Biliary Tract Cancer

Interventions: Drug: M7824

First Posted Date: 2019-02-07

Last Posted Date: 2023-10-25

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 159

Registration Number: NCT03833661

Locations: 🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸
UCSF Mount Zion Medical Ctr, San Francisco, California, United States
🇺🇸
Mayo Clinic in Florida - Department of Neurology, Jacksonville, Florida, United States

and more 30 locations

Avelumab Program Rollover Study

Phase 3

Active, not recruiting

Conditions: Solid Tumors

Interventions: Drug: Avelumab

First Posted Date: 2019-01-24

Last Posted Date: 2025-05-14

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 205

Registration Number: NCT03815643

Locations: 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸
University of California Davis Health System - Comprehensive Cancer Center, Sacramento, California, United States

and more 100 locations

Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer

Phase 1

Completed

Conditions: Locally Advanced Rectal Cancer

Interventions: Drug: Peposertib 100 mg
Drug: Peposertib 250 mg
Drug: Peposertib 150 mg
Drug: Peposertib 50 mg
Drug: Capecitabine
Radiation: Radiotherapy (RT)

First Posted Date: 2018-12-10

Last Posted Date: 2023-03-21

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 19

Registration Number: NCT03770689

Locations: 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸
Yale University - Pediatric Respiratory Medicine, New Haven, Connecticut, United States
🇺🇸
Montefiore Medical Center, Bronx, New York, United States

and more 11 locations

Study of Avelumab-M3814 Combinations

Phase 1

Completed

Conditions: Oncology
Solid Tumors

Interventions: Drug: M3814
Drug: Avelumab
Radiation: Radiotherapy

First Posted Date: 2018-10-30

Last Posted Date: 2025-04-10

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 57

Registration Number: NCT03724890

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Inc, Tampa, Florida, United States
🇺🇸
The University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Mount Sinai - PRIME (10707), Lake Success, New York, United States

and more 5 locations

Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer

Phase 1

Completed

Conditions: Ovarian Cancer

Interventions: Drug: M6620
Drug: Avelumab
Drug: Carboplatin

First Posted Date: 2018-10-12

Last Posted Date: 2020-11-13

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 3

Registration Number: NCT03704467

Locations: 🇺🇸
Marin Cancer Care, Inc., Greenbrae, California, United States
🇺🇸
The Stamford Hospital, Stamford, Connecticut, United States
🇺🇸
Covenant Health Care, Saginaw, Michigan, United States

and more 9 locations

M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 3

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: M7824
Drug: Pembrolizumab

First Posted Date: 2018-08-15

Last Posted Date: 2025-04-08

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 304

Registration Number: NCT03631706

Locations: 🇺🇸
Oncology Specialties, PC; Clearview Cancer Institute, Huntsville, Alabama, United States
🇺🇸
Cedars Sinai Medical Center - Inflammatory Bowel Disease Center (Clinic, Los Angeles, California, United States
🇺🇸
UC Irvine Medical Center, Orange, California, United States

and more 116 locations

Tepotinib Hepatic Impairment Trial

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Tepotinib

First Posted Date: 2018-06-06

Last Posted Date: 2024-08-12

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 18

Registration Number: NCT03546608

Locations: 🇺🇸
Qps Mra, Llc, Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy